Trade Medivir B - MEDIVIR CFD

Medivir Company profile

About Medivir AB

Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Medivir AB revenues increased 83% to SEK25.5M. Net loss increased 48% to SEK63.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.44 to -SEK1.19.

Equity composition

01/2007, Rigths Issue, 3 new shares for every 5 shares held @ SEK 29 (Factor: 1.224545). 04/2010, Rights Issue, 1 new share for every 4 shares held @ SEK 62 (Factor: 1.10266). 2/2015, complex stock split (Factor: 1.59182) 1/2021, Rights Issue, 1 new share for every 1 share held @ SEK7 (Factor: 1.21788).